The tumor-promoting effect of TNF-α involves the induction of secretory leukocyte protease inhibitor

被引:18
|
作者
Devoogdt, Nick [1 ]
Revets, Hilde [1 ]
Kindt, Anne [1 ]
Liu, Yuan Qing [1 ]
De Baetselier, Patrick [1 ]
Ghassabeh, Gholamreza Hassanzadeh [1 ]
机构
[1] Vrije Univ Brussel VIB, Dept Mol & Cellular Interact, B-1050 Brussels, Belgium
来源
JOURNAL OF IMMUNOLOGY | 2006年 / 177卷 / 11期
关键词
D O I
10.4049/jimmunol.177.11.8046
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
According to the cancer immunoediting concept., inflammatory mediators play not only a critical role in promoting host protection against cancer but also contribute to cancer cell growth and survival. TNF-alpha is a critical factor in this network. However, the mechanisms underlying the tumor-promoting effect of TNF-a have not been fully elucidated yet. We previously reported that in vitro culture of Lewis lung carcinoma XL cells with TNF-alpha-producing macrophages resulted in enhanced resistance toward TNF-alpha-mediated lysis and increased malignancy of the 3LL cells. In this study, we analyzed the effects of endogenous TNF-alpha on TNF-alpha resistance and malignant behavior in vivo of low-malignant/TNF-alpha-sensitive 3LL-S cells and cancer cells derived from 3LL-S tumors that developed in wild-type or TNF-alpha(-/-) mice. Interestingly, 3LL-S cells acquired a malignant phenotype in vivo depending on the presence of host TNF-a, whereas acquisition of TNF-alpha resistance was TNF-alpha-independent. This result suggested that malignancy-promoting characteristics of 3LL-S cells other than TNF-alpha resistance are influenced in vivo by TNF-a. We previously identified the malignancy-promoting genes, secretory leukoeyte protease inhibitor (SLPI) and S100A4, as being upregulated in 3LL-S cells upon their s.c. growth in wild-type mice. In this study, we show that SLPI, but not S100A4, was induced in 3LL-S cells both in vitro and in vivo by TNF-a, and that silencing of in vivo induced 3LL-S SLPI expression using RNA interference abrogated in vivo progression but (lid not influence TNF-alpha resistance. These data indicate that SLPI induction may be one mechanism whereby TNF-alpha acts as an endogenous tumor promoter.
引用
收藏
页码:8046 / 8052
页数:7
相关论文
共 50 条
  • [41] Expression of secretory leukocyte protease inhibitor in middle ear cholesteatoma
    Jung-Kyu Lee
    Sung-Won Chae
    Jae-Gu Cho
    Heung-Man Lee
    Soon-Jae Hwang
    Hak-Hyun Jung
    European Archives of Oto-Rhino-Laryngology and Head & Neck, 2006, 263 : 1077 - 1081
  • [42] PULMONARY DEPOSITION AND DISAPPEARANCE OF AEROSOLIZED SECRETORY LEUKOCYTE PROTEASE INHIBITOR
    STOLK, J
    CAMPS, J
    FEITSMA, HIJ
    HERMANS, J
    DIJKMAN, JH
    PAUWELS, EKJ
    THORAX, 1995, 50 (06) : 645 - 650
  • [43] NEONATAL PLASMA-CONCENTRATIONS OF SECRETORY LEUKOCYTE PROTEASE INHIBITOR
    SVEGER, T
    OHLSSON, K
    SVENNINGSEN, N
    ACTA PAEDIATRICA, 1992, 81 (03) : 270 - 271
  • [44] Anti-inflammatory function of secretory leukocyte protease inhibitor
    Ding, AH
    Zhu, J
    Jin, FY
    Grobmyer, SR
    Nathan, CF
    JOURNAL OF ENDOTOXIN RESEARCH, 1999, 5 (03): : 167 - 169
  • [45] Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages
    Ding, A
    Thieblemont, N
    Zhu, J
    Jin, FY
    Zhang, J
    Wright, S
    INFECTION AND IMMUNITY, 1999, 67 (09) : 4485 - 4489
  • [46] The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA
    Zitnik, RJ
    Zhang, J
    Kashem, MA
    Kohno, T
    Lyons, DE
    Wright, CD
    Rosen, E
    Goldberg, I
    Hayday, AC
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 232 (03) : 687 - 697
  • [47] Potent antimycobacterial activity of mouse secretory leukocyte protease inhibitor
    Nishimura, Junichi
    Saiga, Hiroyuki
    Sato, Shintaro
    Okuyama, Megumi
    Kayama, Hisako
    Kuwata, Hirotaka
    Matsumoto, Sohkichi
    Nishida, Toshirou
    Sawa, Yoshiki
    Akira, Shizuo
    Yoshikai, Yasunobu
    Yamamoto, Masahiro
    Takeda, Kiyoshi
    JOURNAL OF IMMUNOLOGY, 2008, 180 (06): : 4032 - 4039
  • [48] Presence of Secretory Leukocyte Protease Inhibitor in human conjunctiva.
    Sakata, M
    Higa, K
    Enomoto, M
    Tsubota, K
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2001, 42 (04) : S37 - S37
  • [49] Delayed healing and induction of secretory leukocyte protease inhibitor in polycystic ovary syndrome rat skin wounds
    Jeong, Soon-Jeong
    Kim, Sung-Shin
    Bae, Chun-Sik
    Park, Jin-Ju
    Choi, Baik-Dong
    Wang, Guanlin
    Jung, Myung-Ju
    Jang, Hyun-Sun
    Kim, Byung-Ock
    Lim, Do-Seon
    Cho, Young-Sik
    Jeong, Moon-Jin
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 29 (02) : 185 - 194
  • [50] Secretory Leukocyte Protease Inhibitor as a Differential Diagnostic Biomarker of Tumor Emboli in Inflammatory Breast Cancer.
    Robertson, F. M.
    Ye, Z.
    Chu, K.
    Luo, A. Z.
    Wright, M. C.
    Jin, J.
    Barsky, S. H.
    Cristofanilli, M.
    Krishnamurthy, S.
    CANCER RESEARCH, 2011, 71